<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0002109116</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, $0.0001 par value</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>08/20/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001855485</issuerCik>
        <issuerName>Calidi Biotherapeutics, Inc.</issuerName>
        <issuerCusip>320703408</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>4475 EXECUTIVE DRIVE</com:street1>
          <com:street2>SUITE 200</com:street2>
          <com:city>SAN DIEGO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92121</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Gavrilov Ognian Anguelov</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>560000.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>560000.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>560000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <classPercent>7.8</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>This Schedule 13G, which is a first-time filing, is being filed late due to an inadvertent oversight.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Calidi Biotherapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>4475 EXECUTIVE DRIVE, SUITE 200, SAN DIEGO, CALIFORNIA, 92121</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Ognian Anguelov Gavrilov</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>2315 Capitol Avenue, Sacramento, CA 95618</principalBusinessOfficeOrResidenceAddress>
        <citizenship>United States</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>560,000 shares</amountBeneficiallyOwned>
        <classPercent>7.78%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>560,000</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>560,000</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
        <classOwnership5PercentOrLess>N</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11.

</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Gavrilov Ognian Anguelov</reportingPersonName>
      <signatureDetails>
        <signature>Ognian Anguelov Gavrilov</signature>
        <title>Managing Partner</title>
        <date>02/04/2026</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
